Arbor plans to grow its 120-person workforce by 20% to 25% over the next 12 months, its CEO, Devyn Smith, told Insider; it's still fueled by a $215 million Series B round announced last November.Vertex and CRISPR Therapeutics have jointly developed what could be the first CRISPR drug for sickle-cell disease; it's set to be up for an approval decision next year.Vertex said earlier this year that 31 participants in a late-stage study who'd been suffering crippling pain attacks every few months stopped experiencing them in the months after receiving the treatment.Fyodor Urnov, the director of technology and translation at the California nonprofit Innovative Genomics Institute, said the curative power wasn't a given before Vertex's sickle-cell results.And biotechs like Verve Therapeutics, Locus Biosciences, and Excision BioTherapeutics are now testing CRISPR-based therapies in more common diseases, going after heart disease, urinary tract infections, and HIV."